Supporting Information

Synthesis and Structure—Activity Relationship Study of Antimicrobial Auranofin against ESKAPE Pathogens

Bin Wu, Xiaojian Yang, Mingdi Yan*

Department of Chemistry, The University of Massachusetts Lowell, MA 01854

Table of Contents

Scheme S1-S8. Synthesis of 1b-6b, 7d and 8f	
General procedure for qNMR	
¹ H NMR, ¹³ C NMR, ³¹ P NMR, ¹⁹ F NMR and HRMS	
Purity assessment of compounds 1-40 by qHNMR	
FAAS calibration curve Figure S142-S143	S198
MIC/MBC Table S1-S4	
Cytotoxicity of auranofin and analogs Table S5	

Synthesis of 1b.



Scheme S1. Synthesis of compound 1b.

2,3,4,6-Tetra-*O*-acetyl-1-*S*-acetyl-1-thio-β-D-glucopyranose (1b)

This compound was synthesized according to general procedure A from **1a** (1.52 g, 3.70 mmol) and purified by flash column chromatography (ethyl acetate:hexanes = 1:1) to give **1b** as a white solid (1.50 g, 86%). ¹H NMR (500 MHz, CDCl₃) δ 5.24-5.14 (m, 2H, H-3, H-1), 5.08 – 4.97 (m, 2H, H-2, H-4), 4.18 (dd, *J* = 12.5, 4.5 Hz, 1H, H-6a), 4.01 (dd, *J* = 12.5, 2.1 Hz, 1H, H-6b), 3.77 (ddd, *J* = 10.1, 4.4, 2.1 Hz, 1H, H-5), 2.30 (s, 3H, SAc), 1.98 (s, 3H, OAc), 1.94 (s, 3H, OAc), 1.93 (s, 3H, OAc), 1.91 (s, 3H, OAc). The NMR spectrum is consistent with published data.¹

Synthesis of 2b.



Scheme S2. Synthesis of compound 2b.

2,3,4,6-Tetra-*O*-acetyl-1-*S*-acetyl-1-thio-β-D-galactopyranose (2b)

This compound was synthesized from compound **2a** (2.24 g, 3.22 mmol) according to general procedure A and purified by flash column chromatography (ethyl acetate:hexanes =1:1) to give **2b** (1.18 g, 90%) as a pale-yellow solid. ¹H NMR (500 MHz, CDCl₃) δ 5.46 (d, *J* = 3.3 Hz, 1H, H-4), 5.35 – 5.29 (t, *J* = 3.3 Hz, 1H, H-2), 5.25 (d, *J* = 10.4 Hz, 1H, H-1), 5.11 (dd, *J* = 9.7, 3.4 Hz, 1H, H-3), 4.18 – 4.02 (m, 3H, H-6a, H-6b, H-5), 2.39 (s, 3H),

2.15 (s, 3H, SAc), 2.04 (s, 3H, OAc), 2.03 (s, 3H, OAc), 1.98 (s, 3H, OAc). The NMR spectrum is consistent with published data.¹

Synthesis of 3b.



Scheme S3. Synthesis of compound 3b.

3,4,6-Tri-O-acetyl-2-N-acetylamido-2-deoxy-α-D-glucopyranosyl chloride (3a)

Prepared according to reported protocol.² Acetyl chloride (2.0 mL, 28.0 mmol) was added dropwise into a round-bottom flask containing *N*-acetylglucosamine (1.0 g, 4.52 mmol) at 0 °C. The mixture was stirred for 48 h under Ar at rt. DCM (200 mL) was added and the organic layer was washed by water, saturated sodium bicarbonate, brine and dried over MgSO₄. After removing the solvent, the residue was purified by flash column chromatography (ethyl acetate:hexanes = 3:1) to afford **3a** as a white solid (951 mg, 57%). ¹H NMR (500 MHz, CDCl₃) δ 6.19 (d, *J* = 3.7 Hz, 1H, H-1), 5.79 (d, *J* = 8.7 Hz, 1H, NH), 5.32 (dd, *J* = 10.5, 9.6 Hz, 1H, H-3), 5.22 (t, *J* = 9.8 Hz, 1H, H-4), 4.53 (ddd, *J* = 10.7, 8.7, 3.7 Hz, 1H, H-2), 4.32 – 4.23 (m, 2H, H-6a, H-5), 4.17 – 4.10 (m, 1H, H-6b), 2.10 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.05 (s, 3H, OAc), 1.99 (s, 3H, NHAc).

3,4,6-Tri-*O*-acetyl-2-*N*-acetyl-*S*-acetyl-1-thio-β-D-glucosamine (3b)

This compound was synthesized according to general procedure A from **3a** (951 mg, 2.60 mmol), and purified by flash column chromatography (ethyl acetate:hexanes =2:1) to give **3b** as a pale yellow solid (925 mg, 88%). ¹H NMR (500 MHz, CDCl₃) δ 5.58 (d, *J* = 9.7

Hz, 1H, NH), 5.15 (d, J = 10.8 Hz, 1H, H-1), 5.13 (t, J = 9.3 Hz, 1H, H-3), 5.09 (t, J = 9.5 Hz, 1H, H-4), 4.35 (q, J = 10.0 Hz, 1H, H-2), 4.24 (dd, J = 12.5, 4.5 Hz, 1H, H-6a), 4.10 (dd, J = 12.5, 2.2 Hz, 1H, H-6b), 3.78 (ddd, J = 9.6, 4.5, 2.2 Hz, 1H, H-5), 2.37 (s, 3H, SAc), 2.08 (s, 3H, OAc), 2.03 (s, 6H, 2×OAc), 1.92 (s, 3H, NHAc). The NMR spectrum is consistent with published data.¹

Synthesis of 4b.



Scheme S4. Synthesis of compound 4b.

2-Deoxy-2-[[(4-methoxyphenyl)methylene]amino]-β-D-glucopyranose (4ii)

Prepared according to a reported procedure.³ D-Glucosamine hydrochloride **4i** (3.0 g, 13.9 mmol) was dissolved in 1 M NaOH (15 mL), and *p*-anisaldehyde (2.0 mL, 16.7 mmol) was added. The mixture was stirred at RT for 0.5 h then was briefly sonicated for 1 min, and was stirred for another 0.5 h. The white precipitate was filtered off, washed with cold water (30 mL) and EtOH/Et₂O (30 mL, 1:1, v/v), and dried under high-vacuum, yielding **4ii** as a white powder (3.71 g, 89%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.11 (s, 1H), 7.71 – 7.66 (m, 2H), 7.02 – 6.96 (m, 2H), 6.51 (d, *J* = 6.8 Hz, 1H), 4.90 (d, *J* = 5.3 Hz, 1H), 4.79 (d, *J* = 5.6 Hz, 1H), 4.69 (dd, *J* = 7.7, 6.7 Hz, 1H), 4.52 (t, *J* = 5.8 Hz, 1H), 3.80 (s, 3H), 3.73 (ddd, *J* = 11.6, 5.6, 2.2 Hz, 1H), 3.48 (dt, *J* = 11.8, 6.0 Hz, 1H), 3.45 – 3.37 (m, 1H), 3.23 (ddd, *J* = 9.7, 5.9, 2.2 Hz, 1H), 3.14 (ddd, *J* = 9.7, 8.7, 5.3 Hz, 1H), 2.79 (dd, *J* = 9.3, 7.6 Hz, 1H).

1,3,4,6-Tetra-*O*-acetyl-2-deoxy-2-[[(4-methoxyphenyl)-methylene]amino]-β-Dglucopyranose (4iii)

Prepared according to an adapted procedure.³ To a cold mixture of **4ii** (4.0 g, 13.5 mmol,) and DMAP (0.06 g, 0.5 mmol) in pyridine (22 mL) was added acetic anhydride (12 mL) at 0 °C. The reaction was stirred overnight at RT. The reaction mixture was then poured into ice water. A large amount of precipitate formed. The precipitate was collected by filtration, and washed with water and Et₂O. After dried in vacuum overnight, **4iii** was obtained as a white powder (4.6 g, 74%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.28 (s, 1H), 7.74 – 7.60 (m, 2H), 7.07 – 6.93 (m, 2H), 6.06 (d, *J* = 8.2 Hz, 1H), 5.44 (t, *J* = 9.7 Hz, 1H), 4.97 (t, *J* = 9.7 Hz, 1H), 4.33 – 4.16 (m, 2H), 4.01 (dd, *J* = 12.3, 2.1 Hz, 1H), 3.80 (s, 3H), 3.44 (dd, *J* = 9.5, 8.6 Hz, 1H), 2.02 (s, 3H), 1.98 (s, 3H), 1.98 (s, 3H), 1.82 (s, 3H).

1,3,4,6-Tetra-*O*-acetyl-2-amino-2-deoxy-β-D-glucopyranose hydrochloride (4iv)

Prepared according to a reported procedure.³ To a solution of **4iii** (3.6 g, 7.73 mmol) in refluxing acetone (20 mL), 5 M aqueous solution of HCl (2 mL) was added dropwise. After 5 min, a white precipitate started to form. After vigorous stirring for 30 min, the reaction was cooled to RT, and the precipitate was filtered off, and washed successively with acetone and Et₂O. After drying in vacuum overnight, **4iv** was obtained as white powder (2.68 g, 90%). ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.75 (s, 3H, NH₃Cl), 5.90 (d, *J* = 8.6 Hz, 1H, H-1), 5.35 (dd, *J* = 10.4, 9.2 Hz, 1H, H-3), 4.93 (dd, *J* = 10.1, 9.2 Hz, 1H, H-4), 4.19 (dd, *J* = 12.5, 4.5 Hz, 1H, H-6a), 4.05 (ddd, *J* = 10.1, 4.5, 2.3 Hz, 1H, H-5), 4.00 (dd, *J* = 12.5, 2.3 Hz, 1H, H-6b), 3.57 (dd, *J* = 10.4, 8.7 Hz, 1H, H-2), 2.17 (s, 3H, OAc), 2.03 (s, 3H, OAc), 2.00 (s, 3H, OAc), 1.98 (s, 3H, OAc).

1,3,4,6-Tri-*O*-acetyl-2-*N*-trichloroactyl-β-D-glucosamine (4v)

To a solution of **4iv** (1.00 g, 2.61 mmol) in 10 mL of DCM, pyridine (0.84 mL, 10.4 mmol) was added. The solution was brought to 0 °C. Trichloroacetic anhydride (1.21 g, 3.91 mmol) was added. The reaction was stirred overnight, then was poured into 50 mL of 1 M HCl solution followed by extraction with DCM (50 mL×3). The combined organic phase was washed by saturated NaHCO₃, brine, and dried over MgSO₄. After removal of the solvent, the residue was purified by flash column chromatography (ethyl acetate/hexanes=1:2) to afford **4v** as a white solid (1.25 g, 97%). ¹H NMR (500 MHz, CDCl₃) δ 7.21 (d, *J* = 9.5 Hz, 1H, NH), 5.82 (d, *J* = 8.7 Hz, 1H, H-1), 5.40 (dd, *J* = 10.9, 9.4 Hz, 1H, H-3), 5.17 (t, *J* = 9.7 Hz, 1H, H-4), 4.37 – 4.25 (m, 2H, H-2, H-6a), 4.17 (dd, *J* = 12.5, 2.2 Hz, 2H, H-6b), 3.91 (ddd, *J* = 10.0, 4.9, 2.2 Hz, 1H, H-5), 2.12 (s, 3H, OAc),

2.11 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.07 (s, 3H, OAc). The NMR spectrum is consistent with published data.⁴

3,4,6-Tri-*O*-acetyl-2-*N*-trichloroactyl-*S*-acetyl-1-thio-β-D-glucosamine (4b)

To a solution of 4v (350 mg, 0.71 mmol) in 3 mL of dry DCM, 4 mL of 33% wt HBr/AcOH solution was added dropwise at 0 °C. The reaction was brought to RT and was further stirred for 2 h. After diluting with 30 mL of DCM, the reaction mixture was poured into 60 mL of ice water and was extracted with DCM 3 times. The combined organic phase was washed by saturated NaHCO₃ solution, water, brine, and dried over Na₂SO₄. After removing the solvent by rotovap evaporation, the crude bromide product 4a was obtained and was used immediately in the next step without further purification. To a solution of this crude 4a in 8 mL of acetone, KSAc (162 mg, 1.42 mmol) was added. The reaction mixture was stirred at RT for 3 h. After removing the solvent by rotovap evaporation, 30 mL of DCM, 10 mL of water and 20 mL of brine were added to the residue. The mixture was extracted by DCM 2 times. The combined organic phase was dried over Na₂SO₄ then was purified by flash column chromatography (ethyl acetate/hexanes=1:2) to afford **4b** as an orange solid (285 mg, 79% over 2 steps). ¹H NMR (500 MHz, CDCl₃) δ 7.61 (d, J = 9.8 Hz, 1H, NH), 5.55 (dd, J = 10.4, 9.6 Hz, 1H, H-3), 5.37 (d, J = 10.7 Hz, 1H, H-1), 5.18 (t, J = 9.8 Hz, 1H, H-4), 4.38 (q, J = 10.4 Hz, 1H, H-2), 4.27 (dd, J = 12.6, 5.1 Hz, 1H, H-6a), 4.15 (dd, J = 12.5, 2.2 Hz, 1H, H-6b), 3.92 (ddd, J = 10.1, 5.1, 2.2 Hz, 1H, H-5), 2.38 (s, 3H, SAc), 2.11 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.06 (s, 3H, OAc). ¹³C NMR (126 MHz, CDCl₃) § 193.14, 171.71, 170.68, 169.37, 162.20, 92.37, 80.88, 76.84, 73.42, 68.13, 62.15, 53.88, 30.85, 20.77, 20.63, 20.56.

Synthesis of 5b.



Scheme S5. Synthesis of compound 5b.

2,3,4,6-Tetra-O-acetyl- α -D-glucopyranosyl (1 \rightarrow 4)-2,3,6-tri-O-acetyl-l-S-acetyl-1-thio- β -D-glucopyranose (5b)

This compound was synthesized according to general procedure A and purified by flash column chromatography (ethyl acetate: hexanes =1:1) to give **5b** as a viscous solid in 82% yield. ¹H NMR (500 MHz, CDCl₃) δ 5.38 (d, J = 3.7 Hz, 1H, H-1'), 5.37 – 5.23 (m, 3H, H-3',H-3, H-1), 5.12 – 4.90 (m, 2H, H-4', H-2), 4.84 (dd, J = 10.4, 4.0 Hz, 1H, H-2'), 4.43 (dd, J = 12.3, 2.3 Hz, 1H, H-6a), 4.30-4.12 (m, 2H, H-6b, H-6'a), 4.10 - 3.72 (m, 4H, H-6)6'b, H-4, H-5', H-5), 2.36 (s, 3H, SAc), 2.11 (s, 3H, SAc), 2.08 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.01 (s, 3H,OAc), 1.99 (s, 3H, OAc), 1.99 (s, 6H, OAc×2). The NMR spectrum is consistent with published data.¹

Synthesis of 6b.



Scheme S6. Synthesis of compound 6b.

2,3,4,6-Tetra-*O*-acetyl- β -D-galactopyranosyl $(1\rightarrow 4)$ -2,3,6-tri-*O*-acetyl-l-S-acetyl-1-

thio- β -D-glucopyranose (6b)

This compound was synthesized according to general procedure A, and purified by flash column chromatography (ethyl acetate/hexanes =1:1) to give **6b** as a viscous solid in 85% yield. ¹H NMR (500 MHz, CDCl₃) δ 5.35 (dd, J = 3.4, 1.0 Hz, 1H, H-4'), 5.25 (t, J = 9.1 Hz, 1H, H-3), 5.21 (d, J = 10.5 Hz, 1H, H-1), 5.11 (dd, J = 10.4, 7.9 Hz, 1H, H-2'), 5.04 (dd, J = 10.4, 9.2 Hz, 1H, H-2), 4.94 (dd, J = 10.4, 3.5 Hz, 1H, H-3'), 4.46 (d, J = 7.9 Hz, 1H, H-1'), 4.45 (dd, J = 12.1, 1.9 Hz, 1H, H-6'a), 4.16 – 4.04 (m, 3H, H-6a, H-6b, H-6'b), 3.89 – 3.84 (m, 1H, H-5'), 3.82 (dd, J = 9.9, 9.0 Hz, 1H, H-4), 3.75 (ddd, J = 10.0, 4.7, 1.9 Hz, 1H, H-5), 2.37 (s, 3H, SAc), 2.15 (s, 3H, OAc), 2.11 (s, 3H, OAc), 2.07 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.96 (s, 3H, OAc). The NMR spectrum is consistent with published data.¹

Synthesis of 7e.



Scheme S7. Synthesis of compound 7e.

2,3,2',3',4',6'-*O*-Acetyl-4,6-di-*O*-benzylidene-α-D-trehalose (7b)

Prepared according to an adapted procedure.⁵ Benzaldehyde dimethyl acetal (1.62 mL, 10.8 mmol), trehalose (2.05 g, 6.0 mmol) and *p*-toluenesulfonic acid monohydrate (0.23 g, 1.2 mmol) were added to DMF (30 mL). The mixture was stirred for 12 hours at 40 °C. After cooling to 0 °C, triethylamine (23.60 g, 232.0 mol) and DMAP (122 mg, 1.00 mmol) were added followed by Ac₂O (13.0 g, 116.0 mmol) dropwise. The reaction mixture was slowly warmed to RT and stirred overnight, after which it was poured into water, and extracted by ethyl acetate 3 times. The combined organic phase was washed by brine twice, and dried over Na_2SO_4 . After removing the solvent, the residue was purified by column chromatography (ethyl acetate/hexanes = 1:1.5 to 1:1) twice to give the desire product as a white amorphous solid (1.60 g, 40%). ¹H NMR (500 MHz, CDCl₃): δ 7.48 - 7.38 (m, 2H, Ar-H), 7.38 - 7.30 (m, 3H, Ar-H), 5.61 (t, J = 9.8 Hz, 1H, H-3'), 5.55 - 5.44 (m, 2H, H-3, PhC*H*), 5.37 (d, *J* = 3.7 Hz, 1H, H-1'), 5.27 (d, *J* = 3.7 Hz, 1H, H-1), 5.09 - 5.02 (m, 2H, H-2' and H-4'), 5.00 (dd, J = 10.2, 4.0 Hz, 1H, H-2), 4.25 (dd, J = 12.2, 5.6 Hz, 1H; H-6a'), 4.17 (dd, J = 10.5, 4.9 Hz, 1H, H-6a), 4.09 (ddd, J = 10.3, 5.7, 2.2 Hz, 1H, H-5'), 4.01 (dd, J = 12.2, 2.2, 1H, H-6b'), 3.97 (td, J = 9.9, 4.9 Hz, 1 H, H-5), 3.75 (t, J = 10.4 Hz, 1H, H-6b), 3.69 (t, J = 9.6 Hz, 1H, H-4), 2.22 - 1.96 (m, 18H, OAc). ¹³C NMR (126 MHz, CDCl₃) δ 170.76, 170.22, 170.03, 169.97, 169.78, 169.78, 136.87, 129.32, 128.41, 126.34, 101.96, 93.49, 92.35, 79.16, 77.43, 70.78, 70.24, 70.16, 69.06, 68.70, 68.28, 63.34, 61.94, 21.01, 20.84, 20.79, 20.79.

4-O-Benzoyl-6-bromo-2,3,2',3',4',6'-penta-O-acetyl-6-deoxy-α, α-D-trehalose (7c)

Prepared according to an adapted procedure.⁵ Compound **7b** (1.44 g, 2.11 mmol) was added into 60 mL of CCl₄ containing NBS (413 mg, 2.32 mmol) and CaCO₃ (232 mg, 2.32 mmol). The mixture was refluxed at 77 °C for 3 hours. After cooling to room temperature, S10

the solution was washed with saturated NaHCO₃ and water. The organic phase was dried over Na₂SO₄, and the filtrate was concentrated in vacuum. The residue was purified by flash column chromatography (ethyl acetate/hexanes = 2:3) to give **7c** as a white solid (1.43 g, 91%). ¹H NMR (500 MHz, CDCl₃): δ 8.15 - 7.95 (d, *J* = 7.3 Hz, 2H, Ar-H), 7.63 (t, *J* = 7.3 Hz, 1H, Ar-H), 7.49 (t, *J* = 7.7 Hz, 2H, Ar-H), 5.71 (t, *J* = 9.8 Hz, 1H, H-3), 5.54 (t, *J* = 9.7 Hz, 1H, H-3'), 5.41 (d, *J* = 3.9 Hz, 1H, H-1), 5.38 (d, *J* = 3.9 Hz, 1H, H-1'), 5.21 - 5.00 (m, 4H, H-2, H-4', H-2' and H-4), 4.25 (m, 2H, H-5' and H-6a'), 4.16 - 3.97 (m, 2H, H-5 and H-6b'), 3.49 - 3.25 (m, 2H, H-6a and H-6b), 2.28 - 1.76 (m, 18H, OAc). ¹³C NMR (126 MHz, CDCl₃) δ 170.81, 170.81, 170.24, 169.73, 169.65, 169.65, 165.59, 134.10, 130.17, 130.17, 128.91, 128.91, 128.65, 92.39, 91.98, 71.82, 70.48, 70.40, 70.29, 69.43, 69.43, 68.80, 68.45, 61.99, 30.75, 21.17, 20.92, 20.90, 20.81, 20.80, 20.78, 20.76.

4-*O*-Benzoyl-6-*S*-acetyl-2,3,2',3',4',6'-penta-*O*-acetyl -α, α-D-trehalose (7d)

Compound **7c** (2.95 g, 3.87 mmol) and KI (1.93 g, 11.6 mmol) was added to a round bottle flask containing 30 mL of DMF. After stirring at 60 °C for 4 h, the mixture was cooled to RT, and KSAc (1.33 g, 11.6 mmol) was added to the mixture. The reaction was stirred under Ar protection overnight. The resulting mixture was poured into 100 mL brine/100 mL water and extracted with ethyl acetate (100 mL×3). The combined organic layer was further washed with 200 mL brine and dried on MgSO₄, concentrated in vacuum. The residue was purified by column chromatography (ethyl acetate/hexanes = 1 to 1) to afford the product as a viscous solid (2.93 g, 96%). ¹H NMR (500 MHz, CDCl₃) δ 8.04 (dd, *J* = 8.3, 1.2 Hz, 1H, Ar-H), 7.60 (t, *J* = 7.5 Hz, 1H, Ar-H), 7.47 (t, *J* = 7.8 Hz, 1H, Ar-H), 5.67 (dd, *J* = 9.8, 9.7 Hz, 1H, H-3), 5.52 (dd, *J* = 9.9, 9.6 Hz, 1H, H-3'), 5.34 (d, *J* = 3.9 Hz, 2H, H-1, H-1'), 5.20 (t, *J* = 9.7 Hz, 1H, H-4), 5.13 – 4.98 (m, 3H, H-2, H-2', H-4'), 4.20 (dd, *J* = 5.11

= 12.2, 6.0 Hz, 1H, H-6a'), 4.07 (dd, J = 12.2, 2.1 Hz, 1H, H-6b'), 4.03 – 3.90 (m, 2H, H-5, H-5'), 3.30 (dd, J = 14.2, 2.6 Hz, 1H, H-6a), 2.91 (dd, J = 14.5, 9.2 Hz, 1H, H-6b), 2.32 (s, 3H, SAc), 2.11 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.08 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 1.93 (s, 3H, OAc). ¹³C NMR (126 MHz, CDCl₃) δ 194.64, 170.73, 170.01, 169.94, 169.85, 169.77, 169.70, 165.66, 133.78, 130.02, 128.95, 128.73, 91.26, 91.12, 72.03, 70.34, 70.31, 69.76, 69.60, 69.53, 68.72, 68.31, 61.93, 30.47, 30.27, 20.80, 20.72, 20.72, 20.72, 20.70, 20.70.

6-S-Acetyl-2,3,4,2',3',4',6'-hexa-*O*-acetyl-α,α-D-trehalose (7e)

Compound **7d** (1.44 g, 1.90 mmol) was dissolved in 50 mL methanol. NaOMe (113 mg, 2.09 mmol) in 3 mL methanol was added to the reaction under Ar protection. The reaction mixture was stirred overnight. After removing the solvent under vacuum, 7 mL of pyridine was added followed by addition of acetic anhydride (2.7 mL, 28.5 mmol) dropwise at 0° C. The reaction was stirred for 16 hours at RT. The reaction mixture was diluted by 100 mL ethyl acetate and poured into 100 mL of water. After extraction for 3 times by ethyl acetate, the combined organic layer was washed with 1 M HCl, saturated NaHCO₃, water, and brine, dried over MgSO₄. After removing the solvent, the residue was purified by column chromatography (ethyl acetate/hexanes = 1:1) to afford the product as a viscous solid (964 mg, 73% over 2 steps). ¹H NMR (500 MHz, CDCl₃) δ 5.44 (t, *J* = 9.7 Hz, 2H, H-4, H-4'), 5.27 (d, *J* = 3.9 Hz, 1H, H-1'), 5.24 (d, *J* = 3.8 Hz, 1H, H-1), 5.05 – 4.89 (m,

4H, H-2, H-2', H-3, H-3'), 4.16 (dd, *J* = 12.2, 6.0 Hz, 1H, H-6'a), 4.01 (dd, *J* = 12.2, 1.9 Hz, 1H, H-6'b), 3.94 (ddd, *J* = 10.0, 5.9, 1.7 Hz, 1H, H-5'), 3.89 – 3.80 (m, 1H, H-5), 3.15 (dd, *J* = 14.2, 2.6 Hz, 1H, H-6a), 2.93 (dd, *J* = 14.2, 7.9 Hz, 1H, H-6b), 2.32 (s, 3H, SAc), 2.07 (s, 3H, OAc), 2.06 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.04 (s, 3H, OAc), 2.02 (s, 3H, OAc), 2.00 (s, 3H, OAc), 2.00 (s, 3H, OAc). ¹³C NMR (50 MHz, CDCl₃) δ 194.73, 170.69, 169.96, 169.85, 169.83, 169.66, 91.45, 91.31, 71.07, 70.20, 70.12, 69.93, 69.70, 69.48, 68.68, 68.30, 61.92, 30.47, 29.93, 20.76, 20.76, 20.73, 20.67. **Synthesis of 8f**.



Scheme S8. Synthesis of compound 8f. Compounds 8a-8d are identical to compounds 4i-4iv (see Scheme S4 and the procedures for their syntheses).

1,2,3,4-Tetra-*O*-acetyl-2-chloroacetamido-2-deoxy-β-D-glucopyranose (8e)

Prepared according to a reported procedure.⁶ To a solution of **8d** (2.53 g, 6.51 mmol) in 30 mL of DCM, pyridine (0.84 mL, 10.4 mmol) was added. The solution was brought to 0 °C. Chloroacetic anhydride (1.67 g, 9.77 mmol) was added. The reaction solution was stirred overnight, then was poured into 50 mL 1 M HCl solution and was extracted by DCM (50

mL×3). The combined organic phase was washed by saturated NaHCO₃, brine, and dried over MgSO₄. After removing the solvent, the residue was purified by flash column chromatography (ethyl acetate/hexanes=2:3) to afford **8e** as a white solid (2.45 g, 89%). ¹H NMR (500 MHz, CDCl₃) δ 6.59 (d, *J* = 9.2 Hz, 1H, NH), 5.81 (d, *J* = 8.6 Hz, 1H, H-1), 5.28 (dd, *J* = 10.5, 9.3 Hz, 1H, H-3), 5.14 (t, *J* = 9.5 Hz, 1H, H-4), 4.29 (dd, *J* = 12.5, 4.7 Hz, 1H, H-6a), 4.22 (dt, *J* = 10.5, 9.0 Hz, 1H, H-2), 4.14 (dd, *J* = 12.5, 2.3 Hz, 1H, H-6b), 3.98 (d, *J* = 1.6 Hz, 2H, CH₂Cl), 3.85 (ddd, *J* = 9.8, 4.6, 2.3 Hz, 1H, H-5), 2.12 (s, 3H, OAc), 2.10 (s, 3H, OAc), 2.05 (s, 3H, OAc), 2.05 (s, 3H, OAc).

1,3,4,6-Tetra-*O*-acetyl-2-((4-mercaptophenyl) sulfanyl)acetamido-2-deoxy-β-Dglucopyranose (8f)

To a solution of compound **8e** (160 mg, 0.378 mmol) and 1,4-benzenedithiol (107 mg, 0.755 mmol) in 5 mL of DCM, TEA (42 mg, 0.415 mmol) was added. The reaction was stirred for 16 h. Then it was concentrated and directly purified by flash column chromatography (ethyl acetate/DCM = 1:1.2) to give the product as a colorless viscous solid (180 mg, 90%). ¹H NMR (500 MHz, CDCl₃) δ 7.22 – 7.17 (m, 2H, Ar-H), 7.15 – 7.09 (m, 2H, Ar-H), 6.81 (d, *J* = 9.2 Hz, 1H, NH), 5.73 (d, *J* = 8.7 Hz, 1H, H-1), 5.24 (dd, *J* = 10.5, 9.3 Hz, 1H, H-3), 5.09 (t, *J* = 9.6 Hz, 1H, H-4), 4.27 (dd, *J* = 12.5, 4.6 Hz, 1H, H-6a), 4.18 (dt, *J* = 10.5, 9.1 Hz, 1H, H-2), 4.11 (dd, *J* = 12.5, 2.2 Hz, 1H, H-6b), 3.82 (ddd, *J* = 9.9, 4.6, 2.3 Hz, 1H, H-5), 3.53 (q, *J* = 16.6 Hz, 2H, SCH₂), 3.45 (s, 1H, SH), 2.08 (s, 3H, OAc), 2.02 (s, 3H, OAc), 1.95 (s, 3H, OAc), 1.88 (s, 3H, OAc). ¹³C NMR (126 MHz, CDCl₃) δ 170.80, 170.74, 169.43, 169.30, 168.43, 131.72, 130.33, 130.06, 129.04, 92.28, 72.94, 72.18, 68.10, 61.76, 53.47, 37.60, 20.83, 20.81, 20.69, 20.57.

Determination of compound purity by absolute qHNMR with internal calibration

The purities of compounds 1-40 were determined by absolute qNMR following the "general guidelines for quantitative 1D ¹H NMR (qHNMR) experiments," provided by the *Journal of Medicinal Chemistry*.

The internal calibrant dimethyl sulfone (DMSO₂) was purchased from Sigma-Aldrich (product number: M81705, batch number: WXBC7924V). The purity of the internal calibrant (P_{IC}) was 100.0% according to the "Certificate of Analysis" of this particular batch provided by the vendor. The absolute qHNMR with internal calibration was conducted on a Bruker Avance Spectrospin DRX500 spectrometer at 298K. The data were obtained at 90° pulse tip angle with an interpulse delay (D₁) of 60 s and an acquisition time of 3.2 s in a non-spinning mode. The FID was obtained following 64 scans of 256 K data points with a 20 ppm width spectral window. The data were processed with the MestReNova 9.0.1 software.

General procedure for qHNMR

Step 1: The weights of the sample (m_s) and the internal calibrant (m_{IC}) were measured on a semi-micro METTLER TOLEDO balance with 0.01 mg accuracy. Then they were fully dissolved in 650 µL of CDCl₃ or 600 µL of D₂O in a 2-mL vial. The resulting solution was transferred into a 5-mm standard NMR tube for analysis.

Step 2: After manual phase and baseline correction, the purest signals of the sample were integrated. The integral of the sample (Int_t) was calculated as the average of all integrated

protons by dividing the sum of all those integrals by the number of protons that give rise the signals. By this procedure, the total number of protons (n_t) is set to 1.

Step 3: The integral of the internal calibrant (DMSO₂, singlet at 3.0-3.2 ppm) and the number of protons that give rise to this signal were recorded as Int_{IC} and n_{IC} ($n_{IC} = 6$).

Step 4: Calculate the molecular weights of the sample (MW_t) and the internal calibrant $(MW_{IC} = 94.13 \text{ g/mol}).$

Step 5: Calculate the purity (*P*) of the sample according to the following equation:

$$P[\%] = \frac{n_{IC} \cdot Int_t \cdot MW_t \cdot m_{IC}}{n_t \cdot Int_{IC} \cdot MW_{IC} \cdot m_s} \cdot P_{IC}$$

References

1. Shu, P.; Zeng, J.; Tao, J.; Zhao, Y.; Yao, G.; Wan, Q., Selective S-deacetylation inspired by native chemical ligation: practical syntheses of glycosyl thiols and drug mercapto-analogues. *Green Chem.* **2015**, *17* (4), 2545-2551.

2. Floyd, N.; Vijayakrishnan, B.; Koeppe, J. R.; Davis, B. G., Thiyl glycosylation of olefinic proteins: S-Linked glycoconjugate synthesis. *Angew. Chem., Int. Ed.* **2009**, *48* (42), 7798-7802.

3. Dąbrowa, K.; Niedbała, P.; Jurczak, J., Engineering light-mediated bistable azobenzene switches bearing urea D-aminoglucose units for chiral discrimination of carboxylates. *J. Org. Chem.* **2016**, *81* (9), 3576-3584.

4. Qin, C.; Schumann, B.; Zou, X.; Pereira, C. L.; Tian, G.; Hu, J.; Seeberger, P. H.; Yin, J., Total synthesis of a densely functionalized plesiomonas shigelloides serotype 51 aminoglycoside trisaccharide antigen. *J. Am. Chem. Soc.* **2018**, *140* (8), 3120-3127.

5. Chen, X.; Wu, B.; Jayawardana, K. W.; Hao, N.; Jayawardena, H. S. N.; Langer, R.; Jaklenec, A.; Yan, M., Magnetic multivalent trehalose glycopolymer nanoparticles for the detection of mycobacteria. *Adv. Healthcare Mater.* **2016**, *5* (16), 2007-2012.

6. Liu, F.; Vijayakrishnan, B.; Faridmoayer, A.; Taylor, T. A.; Parsons, T. B.; Bernardes, G. J. L.; Kowarik, M.; Davis, B. G., Rationally designed short polyisoprenol-Linked PglB substrates for engineered polypeptide and protein N-glycosylation. *J. Am. Chem. Soc.* **2014**, *136* (2), 566-569.



Figure S1. ¹H NMR spectrum of compound 1b in CDCl₃.



Figure S2. ¹H NMR spectrum of compound 1 in CDCl₃.



Figure S3. ¹H NMR spectrum of compound 2b in CDCl₃.



Figure S4. ¹H NMR spectrum of compound 2 in CDCl₃.



Figure S5. ¹³C NMR spectrum of compound 2 in CDCl₃.



S22



Figure S7. ¹H NMR spectrum of compound 3a in CDCl₃.



Figure S8. ¹H NMR spectrum of compound 3b in CDCl₃.



Figure S9. ¹H NMR spectrum of compound 3 in CDCl₃.



Figure S10. ¹³C NMR spectrum of compound 3 in CDCl₃.



---36.93

Figure S11. ³¹P NMR spectrum of compound 3 in CDCl₃.



Figure S12. HRMS of compound 3.



Figure S13. ¹H NMR spectrum of compound 4c in DMSO-d₆.



Figure S14. ¹H NMR spectrum of compound 4d in DMSO-d₆.



Figure S15. ¹H NMR spectrum of compound 4e in CDCl₃.



Figure S16. ¹H NMR spectrum of compound 4f in CDCl₃.



Figure S17. ¹³C NMR spectrum of compound 4f in CDCl₃.



Figure S18. ¹H NMR spectrum of compound 4 in CDCl₃.



Figure S19. ¹³C NMR spectrum of compound 4 in CDCl₃.



--37.58




Figure S21. ¹H NMR spectrum of compound 5b in CDCl₃.



Figure S22. ¹H NMR spectrum of compound 5 in CDCl₃



Figure S23. ¹³C NMR spectrum of compound 5 in CDCl₃



---36.88



Figure S25. HRMS of compound 5.



Figure S26. ¹H NMR spectrum of compound 6b in CDCl₃.



Figure S27. ¹H NMR spectrum of compound 6 in CDCl₃.



Figure S28. ¹³C NMR spectrum of compound 6 in CDCl₃.



--37.35

Figure S29. ³¹P NMR spectrum of compound 6 in CDCl₃.



Figure S30. ¹H NMR spectrum of compound 7d in CDCl₃.



Figure S31. ¹³C NMR spectrum of compound 7d in CDCl₃.



Figure S32. ¹H NMR spectrum of compound 7e in CDCl₃.



Figure S33. ¹³C NMR spectrum of compound 7e in CDCl₃.



Figure S34. ¹H NMR spectrum of compound 7 in CDCl₃.



Figure S35. ¹³C NMR spectrum of compound 7 in CDCl₃.



Figure S36. ³¹P NMR spectrum of compound 7 in CDCl₃.



Figure S37. HRMS of compound 7.



Figure S38. ¹H NMR spectrum of compound 8e in CDCl₃



Figure S39. ¹H NMR spectrum of compound 8f in CDCl₃



Figure S40. ¹³C NMR spectrum of compound 8f in CDCl₃



Figure S41. ¹H NMR spectrum of compound 8 in CDCl₃



Figure S42. ¹³C NMR spectrum of compound 8 in CDCl_{3.}



Figure S43. ¹H NMR spectrum of compound 9 in D₂O.



Figure S44. ¹H NMR spectrum of compound 10 in D₂O.



Figure S45. 13 C NMR spectrum of compound 10 in D₂O.



-37.75

Figure S46. ³¹P NMR spectrum of compound 10 in D_2O .



Figure S47. ¹H NMR spectrum of compound 11 in D₂O





S65



Figure S50. ¹H NMR spectrum of compound 12 in D₂O.



Figure S51. ¹³C NMR spectrum of compound 12 in D_2O .

-37.93

COH COH HO 1 HO -NHAc S-Au-PEt₃



Figure S52. ³¹P NMR spectrum of compound 12 in D₂O.



Figure S53. ¹H NMR spectrum of compound **13** in D₂O.



Figure S54. ¹³C NMR spectrum of compound 13 in D₂O.





Figure S55. ³¹P NMR spectrum of compound 13 in D₂O.



Figure S56. ¹H NMR spectrum of compound 14 in D₂O.


Figure S57. ¹³C NMR spectrum of compound 14 in D₂O.



320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 f1 (ppm)

Figure S58. ³¹P NMR spectrum of compound 14 in D₂O.



Figure S59. ¹H NMR spectrum of compound 15 in CDCl₃.



Figure S60. ¹³C NMR spectrum of compound 15 in CDCl₃.

--36.42









Figure S62. ¹H NMR spectrum of compound 16 in CDCl₃.



Figure S63. ¹³C NMR spectrum of compound 16 in CDCl₃.





Figure S64. ³¹P NMR spectrum of compound 16 in CDCl₃.



Figure S65. ¹H NMR spectrum of compound **17** in CDCl₃.



Figure S66. ¹³C NMR spectrum of compound 17 in CDCl₃.



320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

-37.40





Figure S68. ¹H NMR spectrum of compound 18 in CDCl₃.



Figure S69. ¹³C NMR spectrum of compound 18 in CDCl₃.



320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S70. ³¹P NMR spectrum of compound 18 in CDCl₃.



Figure S71. ¹H NMR spectrum of compound **19** in CDCl₃.



Figure S72. ¹³C NMR spectrum of compound 19 in CDCl₃.



-37.78

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S73. ³¹P NMR spectrum of compound 19 in CDCl₃.







---39.09

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)







Figure S78. ¹H NMR spectrum of compound 21 in CD₃OD.







Figure S80.³¹P NMR spectrum of compound 21 in CD₃OD.



Figure S81. ¹H NMR spectrum of compound 22 in CDCl₃.



Figure S82. ¹³C NMR spectrum of compound 22 in CDCl₃.

--37.57





Figure S83. ³¹P NMR spectrum of compound 22 in CDCl₃.



Figure S84. ¹H NMR spectrum of compound 23 in CDCl₃.



Figure S85. ¹³C NMR spectrum of compound 23 in CDCl₃.



320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -7C f1 (ppm)







Figure S88. ¹H NMR spectrum of compound 24 in CDCl₃.



Figure S89. ¹³C NMR spectrum of compound 24 in CDCl₃.





Figure S91. ¹H NMR spectrum of compound 25 in CDCl₃.



--33.15



Figure S92. ³¹P NMR spectrum of compound 25 in CDCl₃.


Figure S93. ¹H NMR spectrum of compound 26 in CDCl₃.



Figure S94. ¹³C NMR spectrum of compound 26 in CDCl₃.





320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S95. ³¹P NMR spectrum of compound 26 in CDCl₃.



Figure S96. ¹H NMR spectrum of compound 27 in CDCl₃.



Figure S97. ¹³C NMR spectrum of compound 27 in CDCl₃.



33.35

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S98. ³¹P NMR spectrum of compound 27 in CDCl₃.



Figure S99. ¹H NMR spectrum of compound 28 in CDCl₃.



S116



--29.49

Figure S101. ³¹P NMR spectrum of compound 28 in CDCl₃.



Figure S102. ¹H NMR spectrum of compound 29 in CDCl₃.



Figure S103. ¹³C NMR spectrum of compound 29 in CDCl₃.



--30.14

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S104. ³¹P NMR spectrum of compound 29 in CDCl₃.





Figure S106. ¹H NMR spectrum of compound 30 in CDCl₃.



Figure S107. ¹³C NMR spectrum of compound 30 in CDCl₃.



--31.86

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)







Figure S110. ¹H NMR spectrum of compound 31 in CDCl₃.



Figure S111. ¹³C NMR spectrum of compound 31 in CDCl₃.



---3.47

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S112. ³¹P NMR spectrum of compound 31 in CDCl₃.



Figure S113. ¹H NMR spectrum of compound 32 in CDCl₃.



Figure S114. ¹³C NMR spectrum of compound 32 in CDCl₃.



-27.07

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S115. ³¹P NMR spectrum of compound **32** in CDCl₃.



Figure S116. ¹H NMR spectrum of compound 33 in CDCl₃.



Figure S117.¹³C NMR spectrum of compound 33 in CDCl₃.



---36.93

Figure S118. ³¹P NMR spectrum of compound 33 in CDCl₃.



Figure S119. ¹H NMR spectrum of compound 34 in CDCl₃.



Figure S120.¹³C NMR spectrum of compound 34 in CDCl₃.



---33.82

320 310 300 290 280 270 260 250 240 230 220 210 200 190 180 170 160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10 0 -10 -20 -30 -40 -50 -60 -70 f1 (ppm)

Figure S121.³¹P NMR spectrum of compound 34 in CDCl₃.



Figure S122. ¹H NMR spectrum of compound 35 in CDCl₃.



Figure S123. ¹³C NMR spectrum of compound 35 in CDCl₃.

-35.38

Aco OAc Aco OAc S-Au P



Figure S124. ³¹P NMR spectrum of compound 35 in CDCl₃.





Figure S126. ¹H NMR spectrum of compound 36 in CDCl₃.



Figure S127.¹³C NMR spectrum of compound 36 in CDCl₃.

-32.62












Figure S130. ¹H NMR spectrum of compound 37 in D₂O.



Figure S131.¹³C NMR spectrum of compound **37** in D₂O.



Figure S132.³¹P NMR spectrum of compound **37** in D₂O.



Figure S133. ¹H NMR spectrum of compound **38** in D₂O







Figure S136. ¹H NMR spectrum of compound 39 in D₂O



Figure S137.¹³C NMR spectrum of compound **39** in D₂O.



---1.98

Figure S138. ³¹P NMR spectrum of compound 39 in D₂O.



Figure S139. ¹H NMR spectrum of compound 40 in CDCl₃.





Determination of purity of Compounds 1 – 40 by qHNMR.

Compound 1 in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **2** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **3** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound 4 in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **5** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **6** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound 7 in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **8** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **9** in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **10** in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **11** in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **12** in D₂O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **13** in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound 14 in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **15** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **16** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **17** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **18** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **19** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **20** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **21** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **22** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **23** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).


Compound **24** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **25** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **26** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **27** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **28** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **29** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **30** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **31** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **32** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **33** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **34** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **35** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **36** in CDCl₃ with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **37** in D₂O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **38** in D_2O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **39** in D₂O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).



Compound **40** in D₂O with the addition of dimethyl sulfone (DMSO₂, 100.0%) as internal standard (500 MHz).





Figure S142. Calibration Curve A of compound 40 in *n*-octanol-saturated water.



Figure S143. Calibration Curve B of compound 40 in water-saturated *n*-octanol.

	A. baumannii	baumannii P. aeruginosa E. cloacae		K. pneumoniae S. aureus		E. faecium	E. coli	ΙοσΡ	
	NCTC 13420	NCTC 13437	NCTC 13405	ATCC 700603	JE2 (USA300)	ATCC 700221	ATCC 25922	Lug I	
1	32 (32)	256 (256)	128 (128)	256 (256)	0.03 (0.06)	0.12/0.06 (0.25)	16 (16)	0.56	
2	32 (64)	256 (256)	256 (256)	>256 (>256)	0.03 (0.06)	0.12/0.25 (0.25)	16 (16)	0.38	
3	16 (32)	128 (128)	32 (64)	128 (128)	0.03/0.06 (0.06)	0.06 (0.25)	8 (8)	0.26	
4 ^f	64 (128)	>256	>256	>256	0.008 (0.01)	0.06 (0.12)	16 (16)	1.01	
5 ^f	32 (32)	128 (128)	64 (64)	>256	0.008 (0.06) 0.03/0.06 (0.12)		16 (16)	0.45	
6 ^g	64 (128)	128 (128)	256 (256)	>256	0.03 (0.12)	0.12 (0.25)	32 (32)	1.04	
7°	16 (16)	>256	32 (32)	>256	0.004/0.008 (0.008)	0.06 (0.12)	32 (32)	-0.28	
8 ^f	64/16 (16)	>256	128/256	>256	0.03/0.008 (0.12)	0.03/0.06 (0.25)	128/>256 (128)	-0.36	
9	32/8 (128)	256 (256)	64 (64)	256 (256)	0.03/0.06 (0.25)	0.06 (1)	16 (16)	-0.81	
10	16 (16)	128 (128)	32 (32)	128 (128)	0.01 (0.06)	0.06/0.12 (0.25)	8 (8)	-0.73	
11	16 (32)	256 (256)	64 (128)	256 (256)	0.01/0.03 (0.06)	0.03/0.06 (0.25)	8 (8)	-0.59	
12	8/16 (64)	256 (256)	64 (128)	256 (256)	0.008 (0.03)	0.03/0.06 (0.25)	4/2 (4)	-0.89	
13	16/32 (128)	256 (256)	128 (128)	256 (256)	0.01/0.03 (0.06)	0.06 (0.25)	16 (16)	-1.81	
14	16 (16)	256 (256)	128 (128)	>256 (>256)	0.03/0.06 (0.06)	0.06/0.12 (0.25)	8 (8)	-1.69	

Table S1. MIC/MBC $(\mu g/mL)^a$ of Group 1 analogs having varying thio sugar structures.

^aAssays were repeated twice. Only one value is presented unless both data are shown.

Lowest precipitation concentration at ^b4, ^c8, ^d16, ^e32 ^f64, ^g128 μ g/mL.

	A. baumannii	P. aeruginosa	E. cloacae	K. pneumoniae	S. aureus	E. faecium	E. coli	LagD
	NCTC 13420	NCTC 13437	NCTC 13405	ATCC 700603	JE2 (USA300)	ATCC 700221	ATCC 25922	L0g P
1	32 (32)	256 (256)	128 (128)	256 (256)	0.03 (0.06)	0.12/0.06 (0.25)	16 (16)	0.56
15 ^f	32/8 (>256)	128 (128)	32 (256)	>256 (>256)	0.008 (0.25)	0.25 (0.5)	64 (64)	2.20
16 ^g	8/16 (8)	128 (128)	8/32 (16/32)	64 (64)	0.004 (0.25)	0.01 (0.06)	16 (16)	0.61
17 ^d	8 (8)	64 (64)	16 (16)	16 (16)	0.01/0.03 (0.03)	0.01 (0.06)	4 (4)	1.36
18 ^f	16 (16)	128 (128)	64 (64)	64 (64)	0.008 (0.12)	0.01/0.06 (0.12)	16 (16)	2.01
19 ^e	>256	>256	>256	>256	0.0002/0.008 (0.008)	0.03/0.06 (0.25)	>256	>3.28
20 ^e	256 (>256)	>256	>256	>256	0.01/0.06 (0.12)	0.01 (0.12)	>256	>3.18
21 ^e	4 (32)	16 (16)	4/2 (32)	8 (8)	0.01 (0.01)	0.06/0.12 (0.25)	4 (4)	1.19
22 ^d	8 (32)	128 (128)	16 (64)	32 (32)	0.002/0.007 (0.01)	0.06/0.12 (0.25)	32 (32)	1.75
23 ^g	32/16 (64)	64 (64)	16 (64)	64 (64)	0.004 (0.06)	0.25 (0.5)	32 (32)	2.08

Table S2. MIC/MBC $(\mu g/mL)^a$ of Group 2 analogs having an aromatic or aliphatic thiol ligand.

^aAssays were repeated twice. Only one value is presented unless both data are shown.

Lowest precipitation concentration at ^b4, ^c8, ^d16, ^e32 ^f64, ^g128 μ g/mL.

	A. baumannii	baumannii P. aeruginosa E. cloa		e K. pneumoniae		E. faecium	E. coli	Log D
	NCTC 13420	NCTC 13437	NCTC 13405 ATCC 700603		aureusjez (USA300)	ATCC 700221 ATCC 25922		Lug I
24	4/2 (4)	16 (16)	1 (1)	4/2 (4)	0.03/0.06 (0.5)	0.12 (1)	2 (2)	0.16
25	8/4 (8)	32 (64)	8 (8)	16 (16)	0.004/0.007 (0.06)	0.03/0.06 (0.25)	8 (8)	1.74
26 ^e	64/32 (64)	32 (32)	>256	64 (64)	1 (2)	2 (2)	>256	>3.99
27 ^d	64/8 (258)	>256	>256	>256	0.5/1 (2)	2 (2)	>256	>3.94
28°	>256	>256	>256	>256	1 (2)	2 (2)	>256	>4.09
29 ^d	32/16 (128)	>256	>256	>256	0.5 (2)	1/2 (2)	>256	>4.04
30 °	>256	>256	>256	>256	2/1 (8)	>256	>256	>3.94
31 ^g	8/4 (64)	64 (64)	2 (2)	8 (8)	0.06 (0.12)	0.12/0.25 (0.5)	4 (4)	0.35
1	32 (32)	256 (256)	128 (128)	256 (256)	0.03 (0.06)	0.12/0.06 (0.25)	16 (16)	0.56
32 ^e	64 (>256)	>256	>256	>256	2 (2)	4/2 (2)	>256	>4.32
33°	>256	>256	>256	>256	1/2 (2)	4 (4)	>256	>3.87
34 ^c	>256	>256	>256	>256	1 (2)	4/2 (4)	>256	>3.03
35°	>256	>256	>256	>256	1 (2)	4/2 (4)	>256	>3.04
36°	>256	>256	>256	>256	4 (8)	32 (64)	>256	>3.55

Table S3. MIC/MBC (µg/mL)^a of Group 3 analogs having a trialkyl- or triaryl-phosphine ligand.

^aAssays were repeated twice. Only one value is presented unless both data are shown.

Lowest precipitation concentration at ^b4, ^c8, ^d16, ^e32 ^f64, ^g128 µg/mL.

	A. baumannii	P. aeruginosa	E. cloacae	K. pneumoniae	S. aureus	E. faecium	E. coli	LegD
	NCTC 13420	NCTC 13437	NCTC 13405	ATCC 700603	JE2 (USA300)	ATCC 700221	ATCC 25922	Log P
1	32 (32)	256 (256)	128 (128)	256 (256)	0.03 (0.06)	0.12/0.06 (0.25)	16 (16)	0.56
3 1 ^g	8/4 (64)	64 (64)	2 (2)	8 (8)	0.06 (0.12)	0.12/0.25 (0.5)	4 (4)	0.35
37	8/2 (8)	>256	2/4 (8)	16 (16)	0.12/0.25 (0.5)	0.12/0.25 (0.25)	4 (4)	-1.63
38	8/4 (8)	>256 (>256)	2 (2)	16 (16)	0.12 (0.12)	0.12/0.25 (0.25)	4 (4)	-1.88
39	8/4 (8)	>256 (>256)	4/8 (8)	16 (64)	0.25 (0.25)	0.12/0.25 (0.25)	4/16 (16)	-2.03
40 ^f	2/1 (8)	32/8 (32)	1(1)	4 (8)	0.12 (0.25)	0.12 (0.12)	0.5/2 (4)	-0.15

Table S4. MIC/MBC $(\mu g/mL)^a$ of analogs having trimethylphosphine ligand.

^aAssays were repeated twice. Only one value is presented unless both data are shown.

Lowest precipitation concentration at ^b4, ^c8, ^d16, ^e32 ^f64, ^g128 µg/mL.

1	2	3	4	5	6	7
7.7±1.3	10.5±0.2	30.9±5.8	7.9±0.1	15.2±0.3	29.8±3.2	14.4 ± 0.0
8	9	10	11	12	13	14
15.8±0.1	30.2±0.1	16.9±0.5	17.2±1.1	29.2±4.8	32.9±4.6	31.0±2.4
15	16	17	18	19	20	21
4.3±0.2	7.5±0.1	6.5±1.1	7.2±0.7	5.5±1.3	3.1±0.2	7.3±1.7
22	23	24	25	26	27	28
6.4±2.4	4.6±0.2	15.9±0.7	9.5±0.1	4.7±0.0	$12.0{\pm}1.8$	9.4±1.7
29	30	31	32	33	34	35
13.2±1.0	85.6±26.1	13.1±2.3	2.5±0.3	3.1±0.1	3.8±0.1	2.9±0.1
36	37	38	39	40		
18.3±2.2	52.2±1.0	43.0±3.7	35.5±0.9	12.3±3.1		

Table S5. $IC_{50}~(\mu g/mL)^a$ of auranofin and analogs against A549 cells.

^aData are presented as mean±S.E.M. from two independent experiments.